Pielonefritele cronice &ndash; studiu comparativ bărbați vs femei

Rotaru Larisa; Groppa Liliana; Agachi Svetlana; Russu Eugen; Cazac Victor; Croitor Victoria

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

738

Ultima descărcare din IBN:
2024-01-07 04:53

Căutarea după subiecte
similare conform CZU

616.61-002.2 (3)

Pathology of the urogenital system. Urinary and sexual (genital) complaints. Urology (392)

SM ISO690:2012

ROTARU, Larisa, GROPPA, Liliana, AGACHI, Svetlana, RUSSU, Eugen, CAZAC, Victor, CROITOR, Victoria. Pielonefritele cronice – studiu comparativ bărbați vs femei. In: Arta Medica , 2018, nr. 2(67), p. 15. ISSN 1810-1852.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Arta Medica

Numărul 2(67) / 2018 / ISSN 1810-1852 /ISSNe 1810-1879

Pielonefritele cronice – studiu comparativ bărbați vs femei

Chronic pyelonephritis - comparative study men vs women

CZU: 616.61-002.2

Pag. 15-15

Rotaru Larisa, Groppa Liliana, Agachi Svetlana, Russu Eugen, Cazac Victor, Croitor Victoria

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“

Disponibil în IBN: 18 mai 2018

Descarcă PDF

Rezumat

Pielonefrita cronică este una dintre cele mai frecvente patologii existente, cu afectarea preponderentă a persoanelor apte de muncă. Insuficiența renală cronică terminală este cauzată de pielonefrită cronică in circa 10-15% cazuri. Scopul lucrării a fost determinarea particularităților clinico-evolutive la pacienții cu pielonefrită cronică. Au fost determinați factorii de risc, particularitățile clinico-evolutive și, de asemenea, au fost determinate organele țintă la pacienții cu pielonefrită cronică

Chronic pyelonephritis is one of the most common pathologies with predominantly impaired working conditions. Chronic end-stage renal failure is caused by chronic pyelonephritis in about 10-15% of cases. The purpose of the paper was to determine the clinical-evolutionary peculiarities in patients with chronic pyelonephritis. The risk factors, clinical and evolutionary particularities were determined and, also, there were determined the target organs in patients with chronic pyelonephritis.

Cuvinte-cheie
pielonefrită cronică, factorii de risc, complicaţii.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-62277</cfResPublId>
<cfResPublDate>2018-04-30</cfResPublDate>
<cfVol>67</cfVol>
<cfIssue>2</cfIssue>
<cfStartPage>15</cfStartPage>
<cfISSN>1810-1852</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/62277</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Pielonefritele cronice &ndash; studiu comparativ bărbați vs femei</cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>pielonefrită cronică; factorii de risc; complicaţii.</cfKeyw>
<cfAbstr cfLangCode='RO' cfTrans='o'><p>Pielonefrita cronică este una dintre cele mai frecvente patologii existente, cu afectarea preponderentă a persoanelor apte de muncă. Insuficiența renală cronică terminală este cauzată de pielonefrită cronică in circa 10-15% cazuri. Scopul lucrării a fost determinarea particularităților clinico-evolutive la pacienții cu pielonefrită cronică. Au fost determinați factorii de risc, particularitățile clinico-evolutive și, de asemenea, au fost determinate organele țintă la pacienții cu pielonefrită cronică</p></cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Chronic pyelonephritis is one of the most common pathologies with predominantly impaired working conditions. Chronic end-stage renal failure is caused by chronic pyelonephritis in about 10-15% of cases. The purpose of the paper was to determine the clinical-evolutionary peculiarities in patients with chronic pyelonephritis. The risk factors, clinical and evolutionary particularities were determined and, also, there were determined the target organs in patients with chronic pyelonephritis. &nbsp;</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-12009</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11727</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10626</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29090</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-36237</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-54401</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-12009</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12009-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
<cfFamilyNames>Rotaru</cfFamilyNames>
<cfFirstNames>Larisa</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11727</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11727-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
<cfFamilyNames>Groppa</cfFamilyNames>
<cfFirstNames>Liliana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10626</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10626-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
<cfFamilyNames>Agachi</cfFamilyNames>
<cfFirstNames>Svetlana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29090</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29090-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
<cfFamilyNames>Russu</cfFamilyNames>
<cfFirstNames>Eugen</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-36237</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-36237-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
<cfFamilyNames>Kazak</cfFamilyNames>
<cfFirstNames>Viktor</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-54401</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-54401-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-04-30T24:00:00</cfStartDate>
<cfFamilyNames>Croitor</cfFamilyNames>
<cfFirstNames>Victoria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>